Publication of data in glioblastoma cells

RNS Number : 1988M
Evgen Pharma PLC
20 September 2021
 

Evgen Pharma plc

  ("Evgen" or the "Company")

 

Publication shows effectiveness of SFX-01 in patient derived glioblastoma cells

University of Auckland data

 

Evgen Pharma plc (AIM: EVG), a clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases, notes the publication of data in glioblastoma cells (GBM) generated by Dr Euphemia Leung and Prof Bruce Baguley of the University of Auckland, New Zealand in the pre-print journal BioRxIV (Leung, Wright and Baguley, 2021  https://www.biorxiv.org/content/10.1101/2021.09.14.459936v1).

 

The in vitro data show effectiveness of the Company's lead asset SFX-01 in glioblastoma cells and 3D spheroids from several patients in New Zealand, together with the more commonly used commercially available cell lines. 3D spheroids are aggregations of tumour cells that more closely reflect the structure of tumours in patients. In these in vitro experiments, SFX-01 demonstrated inhibition of glioblastoma cell growth, confirming work previously announced by the Company in another academic centre.

 

Evgen recently announced the grant of Orphan Drug Designation in the USA for Malignant Glioma, affording the programme additional data protection and other incentives.

 

Dr Huw Jones, CEO of Evgen, commented: "This careful and well-controlled set of experiments by Dr Leung and Prof Baguley confirm work communicated to us by Dr Festuccia of the University of L'Aquila, Abruzzo, Italy and are now available through the rapid publication BioRxIV. We noted the effects observed by the Auckland group in a previous communication and the data are now available for inspection via the journal. They serve to confirm the potential efficacy of SFX-01 in cells that are arguably more disease relevant than those more commonly used.''

 

 

Enquiries:

 

Evgen Pharma plc www.evgen.com  

via Walbrook  

Dr Huw Jones, CEO 

 

Richard Moulson, CFO 

 

 

 

finnCap www.finncap.com  

+44 (0)20 7220 0500

Geoff Nash / Teddy Whiley (Corporate Finance) 

 

Alice Lane (ECM) 

 

 

 

Walbrook PR  

+44 (0)20 7933 87870 or evgen@walbrookpr.com

Anna Dunphy / Paul McManus

+44 (0)7876 741 001 / +44 (0)7980 541 893 

     

 

About Evgen Pharma plc

Evgen Pharma is a clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases. The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.

 

Clinical data from the Company's open-label Phase II STEM trial has shown that SFX-01 can halt the growth of progressing tumours in patients with oestrogen-positive (ER+) metastatic breast cancer, and in some cases significantly shrink the tumour, whilst causing very few side effects.

 

The has its headquarters at Alderley Park, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool. It is listed on the AIM market of the London Stock Exchange and trades under the ticker symbol EVG. 

 

For further information, please visit:  www.evgen.com

 

For research on the Company, please visit:  http://evgen.com/investors/analyst-coverage/

 

 

 

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAZZGMLDNGGMZM
UK 100

Latest directors dealings